| MYELOMA MINUTE | Up To The Minute News | 6.18.2020 |
|
 |
 |
| COVID-19 Update: Dexamethasone Works and a New Outbreak in China |
| A U.K. study found that dexamethasone, the ever-present myeloma therapy, is effective in very sick patients with COVID-19 infection. And a second outbreak of the coronavirus has occurred in Beijing. As regions of the U.S. emerge from lockdown, myeloma patients should wear masks, avoid mass gatherings, and “assume that anyone you do not know is a source of COVID-19,” says IMF Chairman Dr. Brian G.M. Durie. |
|
|
 |
| Register Now for This Post-ASCO / Post-EHA Webinar |
| Join IMF Chairman of the Board Dr. Brian G.M. Durie, IMF Chief Medical Officer Dr. Joseph Mikhael, and Michigan State University Clinician Dr. Craig Cole as they discuss current trends in myeloma. These myeloma experts will focus on research from the 2020 American Society of Clinical Oncology annual meeting and the 2020 European Hematology Association annual meeting, both of which were recently held online. This webinar will take place on June 25, 2020 at 1:00 p.m. PT / 4:00 p.m. ET. |
|
|
 |
| Last Chance to Register for This Saturday’s Virtual Race |
| Please join the Inland Empire and Inland Valley Warriors (from the Greater Los Angeles area) for the Second Annual Virtual Walk for Myeloma Miracles fundraiser. Participants can run, walk, bike, or treadmill on their own paths from any location in the U.S. to complete the Virtual Walk by this Saturday, June 20. While folks may not be able to physically walk together, all can come together in spirit to support each other and the IMF’s research to find a cure! |
|
|
 |
| Celebrate Dad and Give to the IMF at the Same Time |
| Father’s Day is this Sunday, June 21, 2020. When you shop smile.amazon.com and choose the International Myeloma Foundation as your preferred charity, Amazon donates a portion of your purchase to the IMF, at no added cost to you. Make your gift to Dad count twice this year! |
|
|
 |
| Listen Now to “A Day in the Life,” a Podcast with Myeloma Patient Stories |
| The “A Day in the Life” podcast features messages of hope and resilience for myeloma patients, caregivers, and their loved ones. This episode features an interview with Jen Curran. Jen shares her story of a being diagnosed with myeloma shortly after giving birth to her first daughter. She provides insight on how to play a proactive role in your care. She also gives her point of view on IMF Board Member Yelak’s Biru’s statement, “We are not our disease.” |
|
|
 |
| Dr. Joseph Mikhael Presents an Overview of the IKEMA trial |
| IMF Chief Medical Officer Dr. Joseph Mikhael (TGen Research Institute, City of Hope — Phoenix) explains the methods, results, and conclusion of this interim analysis of the IKEMA trial, a phase III study in which patients with relapsed refractory multiple myeloma who have undergone 1-3 prior lines of therapy that were randomized 3:2. The primary objective of the study was to demonstrate an increase in progression-free survival (PFS) from the use of isatuximab, Kyprolis, and dexamethasone (Isa-Kd) as opposed to Kyprolis and dexamethasone (Kd). |
|
|
 |
| Dr. Joseph Mikhael and Team’s New Consensus Published in Clinical Myeloma, Lymphoma & Leukemia |
| IMF Chief Medical Officer Dr. Joseph Mikhael (TGen Research Institute, City of Hope — Phoenix) served as lead author of “Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.” These recommendations were published in Clinical Myeloma, Lymphoma & Leukemia. The recommendations discuss how and why selinexor is an encouraging option for “both for [RRMM] patients and providers, but poses a unique challenge with an unfamiliar toxicity profile (especially a first-in-class drug), which can only be overcome by gaining familiarity with the drug by repeated usage of the agent.” |
|
|
 |
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series |
This Week’s Question:
Should minimal residual disease testing be routinely performed? |
|
|
| |
|
|
| |
We Thank Our Sponsors:
|
| Amgen, Bristol-Myers Squibb, Genentech, GSK, Sanofi-Genzyme, and Takeda Oncology |
| We also thank individuals like you for your continued support! |
|
|
| Join the conversation at The International Myeloma Foundation |
 Facebook: /Myeloma |  Twitter @IMFMyeloma |  Instagram @IMFmyeloma
www.myeloma.org |
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine |
We respect your privacy and your preferences for communications of this nature.
Home • Unsubscribe • Privacy Policy |
| View as web page |
